Search research articles
Contact Us
Filters
Showing results (11-20 of 17) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 17 results.
ESMO Open
|
November 22, 2025
Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer
G Zhang, H Ni, L Mishieva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
U A Nitz, O Gluz, M Christgen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 16, 2023
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial
O Gluz, S Kuemmel, U Nitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials
M Graeser, O Gluz, C Zu Eulenburg, et al.
ESMO Open
|
August 15, 2025
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)
M Hamann, M Christgen, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 18, 2026
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914)
O Gluz, U Nitz, M Christgen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2024
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
M Martín, S R Stecklein, O Gluz, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 17) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 17 results.
ESMO Open
|
November 22, 2025
Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer
G Zhang, H Ni, L Mishieva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
U A Nitz, O Gluz, M Christgen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 16, 2023
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial
O Gluz, S Kuemmel, U Nitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials
M Graeser, O Gluz, C Zu Eulenburg, et al.
ESMO Open
|
August 15, 2025
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)
M Hamann, M Christgen, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 18, 2026
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914)
O Gluz, U Nitz, M Christgen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2024
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
M Martín, S R Stecklein, O Gluz, et al.
Page
of 2